Myriad Genetics Inc logo

Myriad Genetics Inc

$ 20.26 +1.09 (+5.69%) 10:08 PM EST
On watch
P/E:
At Loss
P/B:
1.79
Market Cap:
$ 1.64B
Enterprise V:
$ 1.50B
Volume:
680.16K
Avg Vol (2M):
590.00K
Also Trade In:
Volume:
680.16K
Market Cap $:
1.64B
PE Ratio:
At Loss
Avg Vol (2-Month):
590.00K
Enterprise Value $:
1.50B
PB Ratio:
1.79
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies
Name Current Vs Industry Vs History
Cash-To-Debt 1.41
Equity-to-Asset 0.76
Debt-to-Equity 0.15
Debt-to-EBITDA -1.79
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.2
Distress
Grey
Safe
Beneish M-Score -2.12
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 65.2
9-Day RSI 58.44
14-Day RSI 55.07
6-1 Month Momentum % 7.8
12-1 Month Momentum % -19.8

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.73
Quick Ratio 2.58
Cash Ratio 1.5
Days Inventory 31.81
Days Sales Outstanding 55.03
Days Payable 46.57

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.3

Financials (Next Earnings Date:2023-02-24 Est.)

MYGN's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with NAS:MYGN

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 661.4
EPS (TTM) ($) -0.97
Beta 1.73
Volatility % 58.24
14-Day RSI 55.07
14-Day ATR ($) 1.108403
20-Day SMA ($) 18.9425
12-1 Month Momentum % -19.8
52-Week Range ($) 15.38 - 28.45
Shares Outstanding (Mil) 81.03

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Myriad Genetics Inc Filings

Document Form Filing Date
No Filing Data

Myriad Genetics Inc Analysis

Share your research

Headlines

See More
No news.